Cargando…
Baseline Albumin-Bilirubin grade as a predictor of response and outcome of regorafenib therapy in patients with hepatocellular carcinoma: a systematic review and meta-analysis
BACKGROUND: The use of regorafenib in the treatment of hepatocellular carcinoma (HCC) is widespread. Albumin-Bilirubin (ALBI) has been shown to be a potential prognostic marker for regorafenib treatment, but its prognostic value remains controversial. Therefore, we conducted a meta-analysis to inves...
Autores principales: | Xu, Huilin, Cao, Dedong, Zhou, Dingjie, Zhao, Nan, Tang, Xixian, Shelat, Vishalkumar G., Samant, Hrishikesh, Satapathy, Sanjaya K., Tustumi, Francisco, Aprile, Giuseppe, He, Anbing, Xu, Ximing, Ge, Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10588229/ https://www.ncbi.nlm.nih.gov/pubmed/37858207 http://dx.doi.org/10.1186/s12885-023-11488-9 |
Ejemplares similares
-
The prognostic role of neutrophil-to-lymphocyte ratio and C-reactive protein in metastatic colorectal cancer using regorafenib: a systematic review and meta-analysis
por: Zhao, Nan, et al.
Publicado: (2022) -
Assessing Potential Factors Influencing the Efficacy of Immune Checkpoint Inhibitors with Radiation in Advanced Non-Small-Cell Lung Cancer Patients: A Systematic Review and Meta-Analysis
por: Xu, Huilin, et al.
Publicado: (2023) -
On-Treatment Albumin-Bilirubin Grade: Predictor of Response and Outcome of Sorafenib-Regorafenib Sequential Therapy in Patients with Unresectable Hepatocellular Carcinoma
por: Wang, Hung-Wei, et al.
Publicado: (2021) -
The Effect of ShenQi FuZheng Injection in Combination with Chemotherapy versus Chemotherapy Alone on the Improvement of Efficacy and Immune Function in Patients with Advanced Non-Small Cell Lung Cancer: A Meta-Analysis
por: dedong, Cao, et al.
Publicado: (2016) -
Assessing the Relationship Between Liver Metastases and the Survival
of Patients With Non-Small Cell Lung Cancer After Immune Checkpoint Inhibitors
Treatment: A Systematic Review and Meta-Analysis
por: Xu, Huilin, et al.
Publicado: (2023)